vTv Therapeutics reports 2025 net loss of $27M; cash $88.9M; Phase 3 enrollment Q3 2026

vTv Therapeutics Inc.

Full-year 2025 net loss attributable to vTv of $27.0M ($3.20 basic EPS) vs $18.5M ($3.20 basic EPS) in 2024.
Cash and equivalents $88.9M at Dec 31, 2025, up from $36.7M; plus $20M non-dilutive from Newsoara in Feb 2026.
Expect to complete enrollment in Phase 3 CATT1 trial for cadisegliatin in T1D in Q3 2026.
R&D expenses rose to $17.9M in 2025 (2024: $11.5M) driven by higher cadisegliatin clinical spending.
Amended Newsoara license grants global rights to PDE4 inhibitor HPP737 for $20M upfront plus up to $115M milestones and royalties.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.